Valuation : Janux Therapeutics, Inc.

Market Cap 1.1B 950M 891M 813M 1.53B 105B 1.54B 10.57B 4.12B 53.18B 4.14B 4.05B 176B P/E 2026 *
-10.4x
P/E 2027 * -6.81x
Enterprise Value 203M 175M 164M 150M 282M 19.43B 283M 1.95B 760M 9.81B 763M 747M 32.52B EV / Sales 2026 *
6.9x
EV / Sales 2027 * 43.6x
Free-Float
98.51%
Yield 2026 *
-
Yield 2027 * -
1 day-3.99%
1 week+3.68%
Current month+18.85%
1 month+15.73%
3 months+23.58%
6 months+34.35%
Current year+30.65%
1 week 17.97
Extreme 17.97
19.14
1 month 14.86
Extreme 14.86
19.14
Current year 12.12
Extreme 12.12
19.14
1 year 12.12
Extreme 12.12
35.34
3 years 5.65
Extreme 5.65
71.71
5 years 5.65
Extreme 5.65
71.71
10 years 5.65
Extreme 5.65
71.71
Manager TitleAgeSince
Chief Executive Officer 67 2017-05-31
Chief Tech/Sci/R&D Officer - -
Chief Tech/Sci/R&D Officer 57 2020-12-31
Director TitleAgeSince
Director/Board Member 64 2021-03-17
Director/Board Member 55 2021-03-17
Director/Board Member 40 2021-02-28
Date Insider Type Main position Quantity % Market Cap.
7/31/26 Don

Founder

-123,840 0.2061%
7/8/26 Fiscal year

Founder

14,000 0.0233%
6/2/26 Sell

Executive/Senior Manager

-4,059 0.0068%
Change 5-day change 1-year change 3-year change Capi.($)
-3.99%+3.68%-20.64%+71.06% 1.1B
-1.59%-3.35%+52.37%+91.62% 69.54B
-1.34%-0.75%+48.21%+92.23% 64.97B
-2.55%+2.14%+37.97%+12.43% 26.51B
-2.35%-5.75%-12.90%+436.87% 25.89B
-8.37%-12.43%+2.08%-18.39% 25.64B
-0.96%+10.36%+283.06%+429.04% 20.22B
-0.51%+0.23%+35.77%-19.61% 19.98B
-3.13%-5.32%+1.89%+547.32% 15.69B
-1.47%+0.68%+45.51%+142.00% 13.49B
Average -2.63%-1.36%+47.33%+178.46% 28.3B
Weighted average by Cap. -2.26%-1.48%+51.44%+149.78%

Financials

2026 *2027 *
Net sales 29.46M 25.38M 23.8M 21.73M 40.93M 2.82B 41.06M 282M 110M 1.42B 111M 108M 4.71B 8.09M 6.97M 6.54M 5.97M 11.25M 774M 11.28M 77.58M 30.27M 390M 30.39M 29.73M 1.29B
Net income -107M -92.35M -86.58M -79.04M -149M -10.24B -149M -1.03B -401M -5.17B -402M -394M -17.14B -178M -153M -144M -131M -247M -16.98B -248M -1.7B -665M -8.57B -667M -653M -28.43B
Net Debt -899M -775M -726M -663M -1.25B -85.92B -1.25B -8.62B -3.36B -43.37B -3.38B -3.3B -144B -750M -646M -606M -553M -1.04B -71.65B -1.04B -7.19B -2.8B -36.17B -2.81B -2.75B -120B
Logo Janux Therapeutics, Inc.
Janux Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. It has developed three bispecific platforms: Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM). Its TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain. Its TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain. Its clinical candidates include JANX007 and JANX008. JANX007 is a prostate-specific membrane antigen (PSMA-TRACTr) designed to target PSMA, a protein expressed in prostate cancer tumors and the vasculature of other tumors. JANX008 is an epidermal growth factor receptor (EGFR-TRACTr), being studied for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and others.
Employees
113
Date Price Change Volume
26-08-28 US$18.03 -3.99% 637,808
26-08-27 US$18.78 -0.58% 577,335
26-08-26 US$18.89 +1.12% 523,997
26-08-25 US$18.68 +0.43% 1,074,447
26-08-24 US$18.60 +6.96% 1,452,369
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
18
Last Close Price
18.03USD
Average target price
36.24USD
Spread / Average Target
+100.97%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. JANX Stock